References
- Angelo C, Roberto B, Francesco L, Gemelli against COVID-19 post-acute care study group. Persistent symptoms in patients after acute COVID-19. JAMA 2020;324(6):603-5. doi: 10.1001/jama.2020.12603
- Jang SB, Kim DS, Yi EH, Choi GH, Song MD, Lee EK. Telemedicine and the use of Korean medicine for patients with COVID-19 in South Korea: observational study. JMIR Public Health Surveil 2021;7(1):e20236. doi:10.2196/20236.
- Li L, Gou CY, Li XM, Song WY, Wang XJ, Li HY, et al. Effects of Chinese medicine on symptoms, syndrome evolution, and lung inflammation absorption in COVID-19 convalescent patients during 84-day follow-up after hospital discharge: a prospective cohort and nested case-control study. Chin J Integr Med 2021;(online)1-7. doi:10.1007/s11655-021-3328-3
- Shi S, Fang Z, Xiong K, Ye D, Wang W, Wu H, et al. Clinical studies of comprehensive TCM treatment to 30 cases of Qi Yin deficiency type of COVID-19 in its recovery period. Jiangsu J TCM 2021;53(1):25-8. doi 10.19844/j.cnki.1672-397X.2020.00.015
- Li Y, Shi S, Yao Y, Chen A, Cao X. Clinical characteristics of 86 cases COVID-19 convalescent patients. J Liaoning Univ TCM 2020;22(9):122-5. doi: 10.13194/j.issn.1673-842x.2020.09.029
- Jia X, Jiang T, Zhang B, Li S, Hao H, Yang Y, et al. Traditional Chinese medicine treatment for COVID-19 in recovery stage. Shandong J TCM. 2020;39(9):897-902. doi: 10.16295/j.cnki.0257-358x.2020.09.001
- Xiong F, Gong P, Liu Y, Zhang M, G. Feasibility analysis of Chinese medicine for activate blood and resolve stasis on the recovery stage treatment of COVID-19. Research of Integrated Traditional Chinese and Western Medicine 2020;12(4):272-5. doi: 10.3969/j.issn.1674-4616.2020.04.019
- Cong X, Cao Q, He Y, Wang B, Ruan L. Medication thinking and method of pulmonary fibrosis treatment in recovery stage of COVID-19. Acta Chinese Medicine 2020;35(267):1583-6. doi: 10.16368/j.issn.1674-8999. 2020.08.353
- Huang L, Chen M, Tao W, Lei H, Yang CY, Li CD, et al. Traditional Chinese medicine diagnosis and treatment protocol for COVID-19 in recovery period and the case analysis. Fujian J TCM 2020;51(4):4-7. doi: 10.13260/j.cnki.jfjtcm.012050
- Zhao W, Han G, Wang X, Li Y, Zhang H, Zhang Y, et al. Experience on the traditional Chinese medicine treatment of mild and ordinary type of COVID-19 in middle and recovery period. Shanxi J TCM 2020;36(4):36-7.
- Wen L, Wan K, Suai Y, Zhang H. Application of Qingzao Yangrong decoction to convalescent patients with COVID-19. Pharmacology and Clinics of Chinese Materia Medica. 2020;36(2):61-3. doi: 10.13412/j.cnki.zyyl.2020.02.001
- Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital a cohort study. Lancet 2021;397(10270):220-32. doi: 10.1016/S0140-6736(20)32656-8.
- Jeong S, Lee K, Jeong M, Song M, Jang I. A review on the treatment of herbal Medicine for asymptomatically infected COVID-19 patients. J Korean Med 2021;42(1):99-109. Http://dx.doi.org/10.13048/jkm.21007.
- Tenforde MW, Kim SS, Lindsell CJ, Rose EB, Shapiro NI, Files DC, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network - United States, March-June 2020. MMWR Morb Mortal Wkly Rep 2020;69(30):993-8. doi: 10.15585/mmwr.mm6930e1.
- Laura P, Anna A, Donna LM, Max JK, David P, Andrew P, et al. SARS-CoV-2 infects the brain choroid plexus and disrupts the blood-CSF barrier in human brain organoids. Cell Stem Cell 2020;27(6):951-61. doi: 10.1016/j.stem.2020.10.001.
- Zsuzsanna V, Andreas JF, Peter S, Martina H, Rea A, Annelies SZ, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020;295(10234):1417-8. doi: 10.1016/S0140-6736(20)30937-5.
- Rapkiewicz AV, Mai X, Carsons SE, Pittaluga S, Kleiner DE, Berger JS, et al. Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: A case series. EClinicalMedicine 2020;24:100434. doi: 10.1016/j.eclinm.2020.100434
- Tripathi MK, Singh P, Sharma S, Singh TP, Ethayathulla AS, Kaur P. Identification of bioactive molecule from Withania somnifera (Ashwagandha) as SARS-CoV-2 main protease inhibitor. J Biomol Struct Dyn 2020;1-14. doi: 10.1080/07391102.2020.1790425.
- Kim TY, Jeon SE, Jang YH, Gotina L, Won JH, Ju YH, et al. Platycodin D prevents both Iysosome- and TMPRSS2-driven SARS-CoV-2 infection in vitro by hindering membrane fusion. BioRxiv 2020. doi: https://doi.org/10.1101/2020.12.22.423909
- Huang J, Tao G, Liu J, Cai J, Hang Z, Chen JX. Current Prevention of COVID-19: Natural Products and Herbal Medicine. Front Pharmacol 2020;11:588508. doi: 10.3389/fphar.2020.588508.
- Hui DS, Joynt GM, Wong KT, Gomersall CD, Li TS, Antonio G, et al. Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors. Thorax 2005;60(5):401-9. doi: 10.1136/thx.2004.030205.
- Jang I, Baik Y, Bae S, Sun S, Lee J, Han C. An Overview of the Herbal Remedies for Severe Acute Respiratory Syndrome (SARS) in WHO Official Report (2004). J Korean Med 2009;30(3):571-81. uci: G704-000999.2009.30.3.014
- National health commission & national administration of traditional Chinese medicine. Diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 7). Chinese Medica Journal 2020. Available at http://www.gov.cn/zhengce/zhengceku/2020-03/04/content_5486705.html
- Arita R, Ono R, Saito N, Takayama S, Namiki T, Ito T, et al. Kakkonto, shosaikoto, Platycodon grandiflorum root, and gypsum (a Japanese original combination drug known as saikatsugekito): Pharmacological review of its activity against viral infections and respiratory inflammatory conditions and a discussion of its applications to COVID-19. Traditional & Kampo Medicine. 2020;7(3):115-27. https://doi.org/10.1002/tkm2.1258.